Stifel on Regenxbio Inc. (RGNX): 'Positive Functional Update at MDA Bolsters “Best-in-Class” Thesis Ahead of Ph.3 DMD Readout'

March 12, 2026 5:14 AM

Stifel analyst Annabel Samimy reiterated a Buy rating and $42.00 price target on Regenxbio Inc. (NASDAQ: RGNX).The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found